|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma显示文摘AIM To conduct a cohort study of 101 patients with hepatocellular carcinoma (HCC) presenting to a tertiary care medical referral center in Germany between 1997 and 1999.METHODS AND RESULTS Data were retrospectively analyzed by chart review. In 95cases (72 males and 23 females) sufficient data were available for analysis. Twenty-five (29%)of 8.5 patients were HBsAg or anti-HBc positive,21/85 (25%) were anti-HCV positive, and 6/85(7%) were positive for both HBV and HCV-markers. Age was significantly lower in HBV-positive patients than in the other two groups.Thirty-one (34%) of 90 patients had histories of alcohol abuse, In 79/ 94 (84%) patients,cirrhosis was diagnosed. Of these cirrhotic patients, 29/79 (37%) belonged to Child-Pugh's group (CHILD) A, 32/79 (40%) to CHILD B, and 18/79 (23%) to CHILD C. AFP was elevated in 61/91 (67%) patients. A single tumor nodule was found in 38/94 (40%), more than one nodule in 31/94 (34%), and 25/94 (26%) had a diffusely infiltrating tumor, i.e. the tumor margins could not be seen on imaging procedures. Portal vein thrombosis was present in 19/ 94 (20%).Imaging data consistent with lymph node metastases were found in 10/92 (11%), while distant metastases were found in 8/93 (9%).According to Okuda 28/94 (30%) were grouped to stage Ⅰ, 53/94 (56%) were grouped to stage Ⅱ, and 13/94 (14%) were grouped to stage Ⅲ.Survival data were available for 83 patients. The Kaplan-Meier estimate for median survival was 8.4 months. Factors influencing survival were the Okuda score, the presence of portal vein thrombosis, and the presence of ascites. The presence of non-complicated liver cirrhosis by itself, distant metastases, or infection with hepatitis viruses did not influence survival. AFP positivity by itself did not influence survival,though patients with an AFP value greater than 100μg/L did experience shortened survival.Treatment besides tamoxifen or supportive care was associated with prolonged survival. The influence of therapy on survival was most pronounced in Okuda stage Ⅱ patients. There was longer survival in those Okuda stage Ⅱpatients who were treated with percutaneous ethanol injection.CONCLUSION Even in a Iow incidence area such as Germany, the majority of HCC is caused by viral hepatitis and therefore potentially preventable. Reflecting the high proportion of advanced stage tumors in our patients, the median survival was poor. Patients who received active therapy had a longer survival. | Christian Rabe Tillmann Pilz Christoph Klostermann Marc Berna Hans H.Schild Tilman Sauerbruch Wolfgang H.Caselmann | 2001 | World Journal of Gastroenterology2001，7，2： | 60 |
| 2 | HCV-specific cytokine induction in monocytes of patients with different outcomes of hepatitis C显示文摘AIM:Cytokine release by macrophages critically determines the type of immune response to an antigen Therefore.we studied hepatitis C virus (HCV0-Specific induction of interleukins-1β,-10,-12(IL-1β,il-10,IL-12),and tumor necrosis factor-α(TNF-α) in monocytes.METHODS:Intracellular cytokine expression was studied by flow cytometry in 23 patients with chronic hepatitis C,14 anti-HCV seropositives without viremia and 11 controls after stimulation of peripheral blood mononuclear cells with recombinant core,NS3,NS4 NS5a and NS5b proteins .RESULTS:Patients with HCV viremia revealed greater spontaneous exprssion of IL-1β,TNF-α,and IL-10,Furthermore,greater than twofold higher IL-10 epression was induced by the HCV antigens in chronic hepatitis C than in the other two groups (P<0.05) In contrast,neither IL-12 noir TNF-α was induced preferentially.CONCLUSION:In chonic hepatitis C antigen-specific cytokine induction in monocytes is apparently shifted towards predominant IL-10 induction-not counterbalanced by antiviral type 1 cytokines,This may contribute to persistent viral replication. | Rainer P.Woitas Uwe Petersen Dirk Moshage Hans H.Brackmann Bertfried Matz Tilman Sauerbruch Ulrich Spengler | 2002 | World Journal of Gastroenterology2002，8，3： | 15 |
| 3 | Transjugular portosystemic stent shunt in treatment of liver diseases显示文摘INTRODUCTIONMore than 10 years ago ,an interventional technique for the creation of an intrahepatic decompressive shunt between a branch of the portal vein and a main hepatic vein using expandable metallic stents has been intriduced for the treatmint of portal hypertension[1,2],This transjugular portosystemic intrahepatic stent shunt (TIPS) functions as a side to side shunt ,similarly to surgical shunts . | Michael Schepke Tilman Sauerbruch | 2001 | World Journal of Gastroenterology2001，7，2： | 6 |
| 4 | Transjugular intrahepatic portosystemic shunt in refractory chylothorax due to liver cirrhosis显示文摘A pleural effusion containing chylomicrons is termed chylothorax and results from leakage of lymph fluid into the pleural cavity.We report on the case of a 59-year-old woman with severe dyspnea due to a large chylothorax.She was known to have liver cirrhosis but no ascites.There was no history of trauma,cardiac function was normal and thorough diagnostic work-up did not reveal any signs of malignancy.In summary,no other etiology of the chylothorax than portal hypertension could be found.Therapy with diuretics as well as parenteral feeding failed to relieve symptoms.After a transjugular intrahepatic portosystemic shunt(TIPS) had successfully been placed,pleural effusion decreased considerably.Eight months later,TIPS revision had to be performed because of stenosis,resulting in remission from chylothorax.This case shows that even in the absence of ascites,chylothorax might be caused by portal hypertension and that TIPS can be an effective treatment option. | Philipp Lutz Holger Strunk Hans Heinz Schild Tilman Sauerbruch | 2013 | World Journal of Gastroenterology2013，19，7： | 6 |
| 5 | C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma显示文摘AIM: To evaluate prognostic indicators for the outcome of patients with perihilar extrahepatic cholangiocarcinoma in an unselected cohort. METHODS: We retrospectively analyzed 98 patients with perihilar cholangiocarcinoma. Twenty-three patients (23.5%) underwent tumor resection. Patients with non- resectable tumors underwent either transpapillary or percutaneous transhepatic biliary drainage. Additionally, 32 patients (32.7%) received photodynamic therapy (PDT) and 18 patients (18.4%) systemic chemotherapy. Predefined variables at the time of diagnosis and characteristics considering the mode of treatment were entered into a Cox’s proportional hazards model. Included in the analysis were age, tumor stage following the modified Bismuth-Corlette classification, bilirubin, prothrombin time (PT), C-reactive protein (CRP), carbohydrate antigen 19-9 (CA19-9), history of weight loss, surgical resection, chemotherapy and PDT. RESULTS: The Kaplan-Meier estimate of overall median survival was 10.5 (95%CI: 8.4-12.6) mo. In the univariate analysis, low Bismuth stage, low CRP and surgical resection correlated significantly with better survival. In the multivariate analysis, only CRP (P = 0.005) and surgical resection (P = 0.029) were found to be independently predictive of survival in the cohort. Receiver operating characteristic (ROC) analysis identified a CRP level of 11.75 mg/L as the value associated with the highest sensitivity and specificity predicting a survival > 5 mo. Applying Kaplan-Meier analysis, patients with a CRP < 12 mg/L at the time of diagnosis had a signifi cantly longer median survival than patients with higher values (16.2 vs 7.6 mo; P = 0.009).CONCLUSION: This retrospective analysis identif ied CRP level at the time of diagnosis as a novel indicator for the prognosis of patients with perihilar cholangiocarcinoma. It should be evaluated in future prospective trials on this entity. | Thomas Gerhardt Sabine Milz Michael Schepke Georg Feldmann Martin Wolff Tilman Sauerbruch Franz Ludwig Dumoulin | 2006 | World Journal of Gastroenterology2006，12，34： | 5 |
| 6 | Treatment of metastatic colorectal carcinomas by systemic inhibition of vascular endothelial growth factor signaling in mice显示文摘AIM: Tumor angiogenesis has been shown to be promoted by vascular endothelial growth factor (VEGF) via stimulating endothelial cell proliferation, migration, and survival. Blockade of VEGF signaling by different means has been demonstrated to result in reduced tumor growth and suppression of tumor angiogenesis in distinct tumor entities. Here, we tested a recombinant adenovirus, AdsFIt1-3, that encodes an antagonistically acting fragment of the VEGF receptor 1 (Flt-1), for systemic antitumor effects in pre-established subcutaneous CRC tumors in mice. METHODS: Murine colorectal carcinoma cells (CT26) were inoculated subcutaneously into Balb/c mice for in vivo studies. Tumor size and survival were determined. 293 cell line was used for propagation of the adenoviral vectors. Human lung cancer line A549 and human umbilical vein endothelial cells were transfected for in vitro experiments. RESULTS: Infection of tumor cells with AdsFlt1-3 resulted in protein secretion into cell supernatant, demonstrating correct vector function. As expected, the secreted sFlt1-3 protein had no direct effect on CT26 tumor cell proliferation in vitro, but endothelial cell function was inhibited by about 46% as compared to the AdLacZ control in a tube formation assay. When AdsFlt1-3 (5×109 PFU/animal) was applied to tumor bearing mice, we found a tumor inhibition by 72% at d 12 after treatment initiation. In spite of these antitumoral effects, the survival time was not improved. According to reduced intratumoral microvessel density in AdsFIt1-3-treated mice, the antitumor mechanism can be attributed to angiostatic vector effects. We did not detect increased systemic VEGF levels after AdsFlt1-3 treatment and liver toxicity was low as judged by serum alanine aminotransferase determination. CONCLUSION: In this study we confirmed the value of a systemic administration of AdsFIt1-3 to block VEGF signaling as antitumor therapy in an experimental metastatic colorectal carcinoma model in mice. | Volker Schmitz Miroslaw Kornek Tobias Hilbert Christian Dzienisowicz Esbher Raskopf Christian Rabe Tilman Sauerbruch Cheng Qian Wolfgang H Caselmann | 2005 | World Journal of Gastroenterology2005，11，28： | 4 |
| 7 | Distribution and effects of polymorphic RANTES gene alleles in HIV/HCV coinfection - A prospective cross-sectional study显示文摘AIM: Chemokines and their receptors are crucial for immune responses in HCV and HIV infection. RANTES gene polymorphisms lead to altered gene expression and influence the natural course of HIV infection. Therefore,these mutations may also affect the course of HIV/HCV coinfection.METHODS: We determined allele frequencies of RANTES-403 (G→A), RANTES-28 (C→G) and RANTESIN1.1 (T→C) polymorphisms using real-time PCR and hybridization probes in patients with HIV (n = 85), HCV (n= 112), HIV/HCV coinfection (n = 121), and 109 healthy controls. Furthermore, HIV and HCV loads as well as CD4+ and CD8+ cell counts were compared between different RANTES genotypes.RESULTS: Frequencies of RANTES-403 A, RANTES-28 G and RANTES-IN1.1 C alleles were higher in HIV infected patients than in healthy controls (-403: 28.2% vs 15.1%,P = 0.002; -28: 5.4% vs 2.8%, not significant; IN1.1:19.0% vs 11.0%, P = 0.038). In HIV/HCV coinfected patients, these RANTES alleles were less frequent than in patients with HIV infection alone (15.4% P = 0.002;1.7%; P = 0.048; 12.0%; not significant). Frequencies of these alleles were not significantly different between HIV/HCV positive patients, HCV positive patients and healthy controls.CONCLUSION: All three RANTES polymorphisms showed increased frequencies of the variant allele exclusively in patients with HIV monoinfection. The finding that the frequencies of these alleles remained unaltered in HIV/HCV coinfected patients suggests that HCV coinfection interferes with selection processes associated with these alleles in HIV infection. | Golo Ahlenstiel Agathe Iwan Jacob Nattermann Karin Bueren Jürgen K Rockstroh Hans H Brackmann Bernd Kupfer Olfert Landt Amnon Peled Tilman Sauerbruch Ulrich Spengler Rainer P Woitas | 2005 | World Journal of Gastroenterology2005，11，48： | 3 |
| 8 | Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis显示文摘 | Jonel Trebicka Evrim Anadol Natalia Elfimova Ingo Strack Michael Roggendorf Sergei Viazov Inga Wedemeyer Uta Drebber Jürgen Rockstroh Tilman Sauerbruch Hans-Peter Dienes Margarete Odenthal | 2012 | Journal of Hepatology2012，，： | 2 |
| 9 | A citric acid solution is an optimal test drink in the 13C-urea breath test for the diagnosis of Helicobacterpylori infection显示文摘 | Dominguez-Munoz JE Leodolter A Sauerbruch T | 1997 | Gut1997，40，： | 2 |
| 10 | Orthotopic Liver Transplantation in Human-Immunodeficiency-Virus-Positive Patients in Germany显示文摘 | E. Anadol S. Beckebaum K. Radecke A. Paul A. Zoufaly M. Bickel F. Hitzenbichler T. Ganten J. Kittner M. Stoll C. Berg S. Manekeller J. C. Kalff T. Sauerbruch J. K. Rockstroh U. Spengler Raffaele Bruno | 2012 | AIDS Research and Treatment2012，，： | 2 |
| 11 | Adjuvant effective as fluorouracil plusleucovorin for survival in people with resected stage III colon cancer 显示文摘 | Lamberti C Sauerbruch capecitabine is at least as T Glasmacher A | 2005 | Cancer Treat Rev2005，31，8： | 1 |
| 12 | siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo 显示文摘 | Raskoph E Voqu A Sauerbruch T | 2008 | Hepatology2008，49，6： | 1 |
| 13 | Interferon/antioxidant combination therapy for chronic hepatitis C—a controlled pilot trial显示文摘 | Markus P Look Alexandra Gerard Govind S Rao Thomas Sudhop Hans-Peter Fischer Tilman Sauerbruch Ulrich Spengler | 1999 | Antiviral Research1999，，2： | 1 |
| 14 | Generation of activated and antigen-specific T cells with cytotoxic activity after co-culture with dendritic cells显示文摘 | Angela M?rten Tim Greten Carsten Ziske Sabine Renoth Bj?rn Sch?ttker Peter Buttgereit Frank Schakowski Alexander von Rücker Tilman Sauerbruch Ingo G. Schmidt-Wolf | 2002 | Cancer ImmunologyImmunotherapy2002，，1： | 1 |
| 15 | Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure 显示文摘 | LEIFELD L CLEMENS C SAUERBRUCH T | 2010 | Dig Dis Sci2010，55，： | 1 |
| 16 | Impaired CD4 + T cell stimulation of NK cell anti-fibrotic activity may contribute to accelerated liver fibrosis progression in HIV/HCV patients<!-- Doctopic: VH -->显示文摘 | Andreas Gl?ssner Marianne Eisenhardt Pavlos Kokordelis Benjamin Kr?mer Franziska Wolter Hans Dieter Nischalke Christoph Boesecke Tilman Sauerbruch Jürgen K. Rockstroh Ulrich Spengler Jacob Nattermann | 2013 | Journal of Hepatology2013，，： | 1 |
| 17 | SiRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo显示文摘 | Raskopf E Vogt A Sauerbruch T | 2008 | J Hepatol2008，49，6： | 1 |
| 18 | Defective RhoA/Rho-Kinase Signaling Contributes to Vascular Hypocontractility and Vasodilation in Cirrhotic Rats显示文摘 | Martin Hennenberg Erwin Biecker Jonel Trebicka Kerstin Jochem Qi Zhou Martina Schmidt Karl H. Jakobs Tilman Sauerbruch J?rg Heller | 2006 | Gastroenterology2006，，3： | 1 |
| 19 | Mechanisms of extrahepatic vasodilation in portal Hypertension 显示文摘 | Hennenberg M Trebicka J Sauerbruch T | 2008 | Gut2008，57，9： | 1 |
| 20 | Prediction of variceal hemorrhage in cirrhosis: a prospective follow-up studay显示文摘 | Kleber G Sauerbruch T Ansari H | 1991 | Gastroenterology1991，100，51： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员